Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients
- Conditions
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 29
- Registration Number
- NCT03001804
- Locations
- 🇦🇹
Landeskrankenhaus Kirchdorf, Kirchdorf, Austria
🇦🇹Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
🇦🇹Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT03000452
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT02994381
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Celgene
- Registration Number
- NCT02974322
- Locations
- 🇺🇸
UMass Medical Center, Worcester, Massachusetts, United States
🇺🇸Henry Ford Health System, Novi, Michigan, United States
🇺🇸High Desert Gastroenterology, Inc., Lancaster, California, United States
A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Celgene
- Registration Number
- NCT02973191
- Locations
- 🇮🇹
Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy
🇪🇸ICO-Hospital Germans Trias i Pujol, Barcelona, Spain
🇩🇪Universitaetsklinikum Ulm, Ulm, Germany
A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT02957474
- Locations
- 🇬🇧
Richmond Pharmacology, Ltd., Croydon, Surrey, United Kingdom
A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain
- Conditions
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 355
- Registration Number
- NCT02946333
- Locations
- 🇪🇸
Hospital Puerto Real, Puerto Real, Andalusia, Spain
🇪🇸Hospital ICO Durán y Reynals, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital de la Princesa, Madrid, Comunidad De Madrid, Spain
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1
- Registration Number
- NCT02935790
- Locations
- 🇺🇸
NYU Langone Medical Center, New York, New York, United States
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT02934269
- Locations
- 🇺🇸
PPD Phase 1 Unit, Austin, Texas, United States
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
- Conditions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 361
- Registration Number
- NCT02922543
- Locations
- 🇯🇵
Shinko Hospital, Kobe, Hyogo, Japan